TITLE

Dual acting antidepressants: what are the key aspects in terms of short and long term clinical efficacy?

PUB. DATE
January 2007
SOURCE
BMC Psychiatry;2007 Supplement 1, Vol. 7, pS1-S71
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
43707759

 

Related Articles

  • Depressive Disorder Needs an Evidence Base Commensurate With Its Public Health Importance. Geddes, John R.; Furukawa, Toshi A.; Cipriani, Andrea; Barbui, Corrado // Canadian Journal of Psychiatry;Sep2007, Vol. 52 Issue 9, p543 

    The article focuses on the views of the authors regarding the efficacy of antidepressants. According to the authors, antidepressants are efficacious in the short term. They opine that long-term therapy of depression with antidepressants can reduce the risk of relapse in patients who have...

  • The Use of Antidepressant Medications in Early Childhood: Prevalence, Efficacy, and Risk. McCabe, Paul C. // Journal of Early Childhood & Infant Psychology;2009, Issue 5, p13 

    Prescription rates of psychotropic medications for young children have doubled in the past decade, and antidepressants are the second most prescribed medication in the preschool period. This trend of increased antidepressant use among very young children has occurred despite a dearth of safety...

  • Agomelatine in the Treatment of Major Depressive Disorder: Potential for Clinical Effectiveness. Kennedy, Sidney H.; Rizvi, Sakina J. // CNS Drugs;2010, Vol. 24 Issue 6, p479 

    To demonstrate the clinical effectiveness of an antidepressant drug requires evidence beyond short- and long-term efficacy, including a favourable adverse-effect profile and sustained treatment adherence. Under these conditions, patients should experience enhanced social and functional outcomes....

  • Levomilnacipran for the treatment of major depressive disorder: a review. Asnis, Gregory M.; Henderson, Margaret A. // Neuropsychiatric Disease & Treatment;2015, Vol. 11, p125 

    Levomilnacipran (LVM, Fetzima®) was recently approved by the US Food and Drug Administration for the treatment of major depressive disorder. It is a unique dual neurotransmitter reuptake inhibitor. In contrast with other selective serotonin norepinephrine reuptake inhibitors, including...

  • Vilazodone: Another Novel Atypical Antidepressant Drug. Howland, Robert H. // Journal of Psychosocial Nursing & Mental Health Services;Mar2011, Vol. 49 Issue 3, p19 

    This article reviews the novel atypical antidepressant drug vilazodone (Viibryd(tm)), which was approved by the U.S. Food and Drug Administration in January 2011 for the treatment of major depression. Vilazodone is a dual-acting antidepressant drug, with a primary mechanism of action of blocking...

  • The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Nathan, P.J. // Molecular Psychiatry;1999, Vol. 4 Issue 4, p333 

    Hypericum (St John's Wort) is a plant that has been used for centuries as a medicinal herb. Pre-clinical animals studies suggest that hypericum is effective in three major biochemical systems relevant for antidepressant activity, namely the inhibition of the synaptic re-uptake system for...

  • CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Bechtholt-Gompf, Anita; Smith, Karen; John, Catherine; Kang, Hannah; Carlezon, William; Cohen, Bruce; Öngür, Dost // Psychopharmacology;Jun2011, Vol. 215 Issue 4, p689 

    Rationale: In patients, ketamine is a fast-acting antidepressant that can induce long-lasting symptom relief. Similar rapid effects have been reported in rodents, but reports of lasting effects are limited. Objectives: We sought to extend past findings by examining dose-response curves that...

  • dual reuptake inhibitor.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p697 

    A definition of the term "dual reuptake inhibitor," an antidepressant medication, is presented.

  • Long-term depression requires lifelong care. R.M.D. // Cortlandt Forum;02/25/97, Vol. 10 Issue 2, p97 

    Focuses on the effectiveness of continuing antidepressant treatment for long-term depression. Concerns over the side effects of long-term treatment with antidepressants; Determination of the discontinuation of drugs based on clinical assessment.

  • FDA Advisory Committee update.  // Formulary;Nov2005, Vol. 40 Issue 11, p373 

    The article reports that the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee has voted unanimously that long-term efficacy studies for antidepressants should not be required prior to approval. Committee members declared that long-term efficacy data are essential...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics